FDA approves Glaxo's GLP-1
GlaxoSmithKline's weekly GLP-1 diabetes injection has been approved. The FDA made the announcement Tuesday morning. The type-2 diabetes drug, known in past coverage as albiglutide, is officially called Tanzeum.
The FDA was initially set to review the drug in January but said last August that it needed more time to review “information submitted by GSK in response to the [FDA's] requests.”